Particle.news
Download on the App Store
45 ARTICLES
·
14h ago

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

A $149 starter offer alongside a January U.S. launch positions the daily tablet to broaden access.

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams
The new pill will have the same name as the injectable drug
A scale is seen at the Clay-Battelle Community Health Center on March 21, 2017 in Blacksville, West Virginia. The Republican-controlled House of Representatives votes Thursday on a key plank of Trump's legislative agenda -- his plan to repeal and replace Obamacare, his predecessor's crowning domestic policy achievement. / AFP PHOTO / Brendan Smialowski (Photo credit should read BRENDAN SMIALOWSKI/AFP via Getty Images)
Image

Overview

  • The decision authorizes the first oral GLP-1 for chronic weight management in adults with obesity or overweight plus a related condition.
  • Novo Nordisk says U.S. availability begins in January, with a self-pay starting dose priced at $149 under a White House agreement.
  • A 64-week trial showed average weight loss of 16.6% on the 25 mg tablet, or about 13.6% with typical adherence, versus roughly 2% on placebo.
  • Dosing requires an empty stomach with a small amount of water and a 30-minute wait before food or other medicines, and gastrointestinal side effects were common with about 7% discontinuing due to adverse events.
  • Eli Lilly’s competing oral candidate, orforglipron, remains under FDA review with low‑teens weight loss and no food or water restrictions in trials, as analysts estimate pills could capture around 20% of the market by 2030.